Clinical trial participation is associated with improved survival for patients with some genitourinary cancers, but racial, ethnic, age, gender, and socioeconomic disparities appe ...

With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses ...

When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...

This study leverages CDC National Health Interview Survey data to examine financial distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and ...

The evolution of genitourinary cancer treatment includes a shift from monotherapies to combination therapies, improving survival and quality of life. Combining androgen blockers with DNA repair ...

FORT MYERS, Fla., Feb. 26, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO® 2026 ...

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor. Tanya B. Dorff, MD, medical oncologist and ...

The HUGO robotic-assisted surgery system showed a high surgical success rate and favorable rates of grade 3 complications. The Hugo™ robotic-assisted surgery (RAS) system is safe and effective, ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) ...

Cancer is not an outside invader but a biological process, explains Dr. Alexandra Drakaki, medical director of the ...

Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...